Patents by Inventor Roberto DE LUCA

Roberto DE LUCA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to tumour antigens
    Patent number: 11629199
    Abstract: The present application relates to specific binding members that bind carbonic anhydrase IX (CAIX). In particular, the present application relates to the treatment, diagnosis and detection of tumours, e.g. solid tumours, using specific binding members that bind CAIX. The specific binding member may be conjugated to a biocidal or cytotoxic molecule, or to a detectable label.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 18, 2023
    Inventors: Laura Gualandi, Sarah Wulhfard, Francesca Pretto, Catherine Pemberton-Ross, Alessandra Villa, Roberto De Luca
  • Pulley-torsional damper integrated group
    Patent number: 11549579
    Abstract: Pulley-torsional damper integrated group comprising a hub adapted to be rigidly connected to a drive member and a pulley connected to the hub. The hub comprises an inner tubular wall and an outer tubular wall. The pulley is angularly coupled to said hub by means of the ring made of elastomeric material. The elastomeric ring has an outer surface towards the pulley and an inner surface towards the hub, and an adhesive is arranged on at least one of the outer or inner surfaces.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: January 10, 2023
    Assignee: Dayco Europe S.R.L
    Inventors: Giacomo Casagrande, Mattia Roberto De Luca, Miriam Nardone, Roberto Ronchetto
  • IL2 and TNF immunoconjugates
    Patent number: 11274133
    Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: March 15, 2022
    Assignee: PHILOGEN S.P.A.
    Inventors: Roberto De Luca, Francesca Pretto, Sarah Wulhfard
  • IL2 AND TNF MUTANT IMMUNOCONJUGATES
    Publication number: 20210369857
    Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a mutant of tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) or Extra-Domain B (EDB) of fibronectin. The conjugate may be used in the treatment of cancer.
    Type: Application
    Filed: July 23, 2021
    Publication date: December 2, 2021
    Applicant: PHILOGEN S.P.A.
    Inventors: Dario Neri, Roberto De Luca, Sarah Wulhfard
  • IL2 and TNF mutant immunoconjugates
    Patent number: 11103592
    Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a mutant of tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) or Extra-Domain B (EDB) of fibronectin. The conjugate may be used in the treatment of cancer.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: August 31, 2021
    Inventors: Dario Neri, Roberto De Luca, Sarah Wulhfard
  • Antibodies To Tumour Antigens
    Publication number: 20210054095
    Abstract: The present application relates to specific binding members that bind carbonic anhydrase IX (CAIX). In particular, the present application relates to the treatment, diagnosis and detection of tumours, e.g. solid tumours, using specific binding members that bind CAIX. The specific binding member may be conjugated to a biocidal or cytotoxic molecule, or to a detectable label.
    Type: Application
    Filed: December 18, 2018
    Publication date: February 25, 2021
    Inventors: Laura Gaulandi, Sarah Wuihfard, Francesca Pretto, Catherine Pemberton-Ross, Alessandra Villa, Roberto De Luca
  • PULLY-TORSIONAL DAMPER INTEGRATED GROUP
    Publication number: 20200332875
    Abstract: Pulley-torsional damper integrated group comprising a hub adapted to be rigidly connected to a drive member and a pulley connected to the hub. The hub comprises an inner tubular wall and an outer tubular wall. The pulley is angularly coupled to said hub by means of the ring made of elastomeric material. The elastomeric ring has an outer surface towards the pulley and an inner surface towards the hub, and an adhesive is arranged on at least one of the outer or inner surfaces.
    Type: Application
    Filed: May 25, 2017
    Publication date: October 22, 2020
    Applicant: DAYCO EUROPE S.R.L.
    Inventors: Giacomo Casagrande, Mattia Roberto De Luca, Miriam Nardone, Roberto Ronchetto
  • IL2 and TNF Immunoconjugates
    Publication number: 20190284253
    Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.
    Type: Application
    Filed: April 12, 2019
    Publication date: September 19, 2019
    Inventors: Roberto DE LUCA, Francesca PRETTO, Sarah WULHFARD
  • IL2 and TNF immunoconjugates
    Patent number: 10308696
    Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: June 4, 2019
    Assignee: PHILOGEN S.P.A.
    Inventors: Roberto De Luca, Francesca Pretto, Sarah Wulhfard
  • IL2 and TNF Immunoconjugates
    Publication number: 20180079793
    Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.
    Type: Application
    Filed: May 5, 2016
    Publication date: March 22, 2018
    Inventors: Roberto DE LUCA, Francesca PRETTO, Sarah WULHFARD